Advanced
  Home Compare Reports

Comparison with Similar Reports

Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Laboratory), Therapeutic Area (Oncology, Infectious Disease), Mo...

Publisher:        MarketsandMarkets

# of Pages:        374

Rating: 

1 User License $4,950

Publication Date:  July, 2021

Price:       $4,950 / User License




1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.2.1 INCLUSIONS & EXCLUSIONS 49
1.3 MARKET SCOPE 50
FIGURE 1 CRO SERVICES MARKET 50
1.3.1 YEARS CONSIDERED FOR THE STUDY 51
1.4 CURRENCY 51
1.5 LIMITATIONS 51
1.6 STAKEHOLDERS 52
1.7 SUMMARY OF CHANGES 52
2 RESEARCH METHODOLOGY 53
2.1 RESEARCH DATA 53
FIGURE 2 RESEARCH DESIGN 53
2.1.1 SECONDARY DATA 54
2.1.2 PRIMARY DATA 55
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES 55
2.2 MARKET SIZE ESTIMATION 56
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET 56
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020 56
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020 57
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 58
FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2021–2026 59
FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES 59
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 60
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 61
FIGURE 10 DATA TRIANGULATION METHODOLOGY 61
2.5 INSIGHTS FROM PRIMARIES 62
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 62
2.6 RESEARCH ASSUMPTIONS 62
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS 63
2.7 RISK ANALYSIS 63
 
3 EXECUTIVE SUMMARY 64
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 64
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2021 VS. 2026 (USD MILLION) 65
FIGURE 14 CRO SERVICES MARKET, BY MOLECULE TYPE, 2021 VS. 2026 (USD MILLION) 66
FIGURE 15 CRO SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 66
FIGURE 16 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET 67
4 PREMIUM INSIGHTS 68
4.1 CRO SERVICES MARKET OVERVIEW 68
FIGURE 17 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH 68
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY PRODUCT & COUNTRY (2020) 69
FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CRO SERVICES MARKET IN 2020 69
4.3 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 70
FIGURE 19 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2026 70
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2020 71
FIGURE 20 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2020 71
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN CRO SERVICES MARKET FROM 2021 TO 2026 71
5 MARKET OVERVIEW 72
5.1 INTRODUCTION 72
5.2 MARKET DYNAMICS 72
FIGURE 22 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 72
TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS 73
5.2.1 DRIVERS 73
5.2.1.1 Increasing investment in pharmaceutical R&D 73
FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2016 74
FIGURE 24 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021 75
5.2.1.2 Rising number of clinical trials creates significant demand
for CRO services 75
FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021) 75
5.2.1.3 High cost of in-house drug development encourages pharma biotech companies to outsource contract R&D services 76
FIGURE 26 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 76
5.2.1.4 Rising prevalence of orphan and rare diseases creates new revenue pockets for CROs 77
5.2.2 OPPORTUNITIES 77
5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic 77
FIGURE 27 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020) 78
TABLE 2 LIST OF BIOLOGICS APPROVALS BY US FDA, 2020 78
5.2.2.2 Rising demand for specialized testing services among end users 79
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 79
5.2.3 CHALLENGES 80
5.2.3.1 Shortage of skilled professionals for clinical trials 80
5.2.3.2 Requirement for unique analytical testing approach for innovative formation 80
5.2.4 MARKET TRENDS 80
5.2.4.1 Revolutionary shift in CRO services market due to growing adoption of artificial intelligence-based tools for drug discovery 80
5.2.4.2 Increased outsourcing to emerging Asian economies 81
5.2.4.3 CRO industry consolidation 82
TABLE 3 LIST OF ACQUISITIONS 83
5.2.4.4 Integrated end-to-end R&D service solution 83
5.3 RANGES/SCENARIO 84
FIGURE 28 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF CRO SERVICES MARKET 84
5.4 IMPACT OF COVID-19 OUTBREAK ON CRO SERVICES MARKET 84
FIGURE 29 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021 85
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 86
FIGURE 30 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS 87
5.6 PRICING ANALYSIS 87
TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020) 88
5.7 VALUE CHAIN ANALYSIS 88
FIGURE 31 VALUE CHAIN ANALYSIS OF CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE 89
5.8 ECOSYSTEM ANALYSIS 89
FIGURE 32 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET 90
TABLE 5 SUPPLY CHAIN ECOSYSTEM 90
5.9 TECHNOLOGY ANALYSIS 92
5.10 CASE STUDY 92
5.10.1 COVANCE FSPX DATA ANALYSIS USED TO DETERMINE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIAL 92
5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR 92
5.11 REGULATORY ANALYSIS 93
5.12 PORTER’S FIVE FORCES ANALYSIS 96
TABLE 6 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 96
5.12.1 THREAT OF NEW ENTRANTS 96
5.12.2 THREAT OF SUBSTITUTES 97
5.12.3 BARGAINING POWER OF BUYERS 97
5.12.4 BARGAINING POWER OF SUPPLIERS 97
5.12.5 DEGREE OF COMPETITION 97
6 CRO SERVICES MARKET, BY TYPE 98
6.1 INTRODUCTION 99
TABLE 7 CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 99
6.2 CLINICAL RESEARCH SERVICES 99
6.2.1 GROWING NUMBER OF CLINICAL TRIALS AND PARTNERSHIPS WITH CROS PROPEL GROWTH OF SEGMENT 99
TABLE 8 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF JUNE 2021, BY LOCATION 100
TABLE 9 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS 100
FIGURE 33 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020 102
TABLE 10 CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 102
TABLE 11 CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 102
TABLE 12 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 103
TABLE 13 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 103
TABLE 14 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 103
6.2.2 PHASE III CLINICAL RESEARCH SERVICES 104
6.2.2.1 Rising cost of Phase III trials and high number of patients recruited in these trials increases demand for cost effective CRO services 104
TABLE 15 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY 104
TABLE 16 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 105
TABLE 17 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 18 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 19 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 106
6.2.3 PHASE II CLINICAL RESEARCH SERVICES 106
6.2.3.1 Long duration of Phase II studies provides growth
opportunities for CROs 106
TABLE 20 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES 106
TABLE 21 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 107
TABLE 22 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 107
TABLE 23 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 24 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 108
6.2.4 PHASE I CLINICAL RESEARCH SERVICES 108
6.2.4.1 Robust pipeline of pharmaceutical companies drives segment growth 108
TABLE 25 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES 109
TABLE 26 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 109
TABLE 27 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 28 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 29 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 110
6.2.5 PHASE IV CLINICAL RESEARCH SERVICES 111
6.2.5.1 Rising number of CROs providing post-marketing surveillance drives segment growth 111
TABLE 30 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES 111
TABLE 31 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 112
TABLE 32 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 112
TABLE 33 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 112
TABLE 34 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 113
6.3 EARLY-PHASE DEVELOPMENT SERVICES 113
6.3.1 RISING NEED FOR EARLY-PHASE DEVELOPMENT STUDIES FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH 113
FIGURE 34 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2019) 114
TABLE 35 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS 114
TABLE 36 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 115
TABLE 37 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 115
TABLE 38 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 39 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 40 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 116
6.3.2 CHEMISTRY, MANUFACTURING & CONTROL SERVICES 117
6.3.2.1 High demand for CMC services to check quality standards of drugs 117
TABLE 41 CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 117
TABLE 42 NORTH AMERICA: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 117
TABLE 43 EUROPE: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 118
TABLE 44 ASIA PACIFIC: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 118
6.3.3 PRECLINICAL SERVICES 119
6.3.3.1 Rising demand for preclinical services for PK/PD and toxicology testing propels growth of segment 119
TABLE 45 PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 119
TABLE 46 PRECLINICAL SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 120
TABLE 47 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 120
TABLE 48 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 120
TABLE 49 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 121
6.3.4 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES 121
6.3.4.1 Increasing importance of studies to determine pharmacokinetic behavior of drug candidates to drive segment 121
TABLE 50 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 122
TABLE 51 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 52 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 53 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 123
6.3.5 TOXICOLOGY TESTING SERVICES 123
TABLE 54 TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 124
TABLE 55 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 56 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 124
TABLE 57 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 125
6.3.6 OTHER PRECLINICAL SERVICES 125
6.3.6.1 Increasing use of molecular imaging, flow cytometry, and immunohistochemistry to boost segment 125
TABLE 58 OTHER PRECLINICAL SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 125
TABLE 59 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 60 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 126
TABLE 61 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 126
6.3.7 DISCOVERY STUDIES 127
6.3.7.1 Rising importance of CRO services for target identification and validation to promote segment growth 127
TABLE 62 DISCOVERY STUDIES MARKET, BY REGION, 2019–2026 (USD MILLION) 127
TABLE 63 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 127
TABLE 64 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
TABLE 65 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
6.4 LABORATORY SERVICES 128
6.4.1 INCREASING IMPORTANCE OF LAB SERVICES TO ENSURE REGULATORY COMPLIANCE TO PROPEL SEGMENT GROWTH 128
TABLE 66 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 129
TABLE 67 LAB SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 129
TABLE 68 LAB SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 130
TABLE 69 NORTH AMERICA: LAB SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 130
TABLE 70 EUROPE: LAB SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 130
TABLE 71 ASIA PACIFIC: LAB SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 131
6.4.2 ANALYTICAL TESTING SERVICES 131
6.4.2.1 Increasing demand for analytical testing for all stages of drug development drive growth of segment 131
TABLE 72 ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 73 ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 132
TABLE 74 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 132
TABLE 75 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 132
TABLE 76 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 133
6.4.3 PHYSICAL CHARACTERIZATION 133
6.4.3.1 Increasing demand for physical characterization to reduce risk of product failure drives segment growth 133
TABLE 77 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 134
TABLE 78 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 134
TABLE 79 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 134
TABLE 80 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 135
6.4.4 RAW MATERIAL TESTING 135
6.4.4.1 High demand for testing services to ensure quality and purity of raw materials drives growth of segment 135
TABLE 81 RAW MATERIAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 136
TABLE 82 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 136
TABLE 83 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 136
TABLE 84 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 137
6.4.5 BATCH RELEASE TESTING 137
6.4.5.1 Comprehensive portfolio of batch-release testing services offered by CROs to propel segment growth 137
TABLE 85 BATCH RELEASE TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 138
TABLE 86 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 138
TABLE 87 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 138
TABLE 88 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 139
6.4.6 STABILITY TESTING 139
6.4.6.1 Used to ensure long-term quality, safety, and efficacy of pharmaceutical products 139
TABLE 89 STABILITY TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 140
TABLE 90 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 140
TABLE 91 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 140
TABLE 92 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 141
6.4.7 OTHER ANALYTICAL TESTING 141
6.4.7.1 Demand for analytical method validation, cleaning validation, and microbial testing to propel segment growth 141
TABLE 93 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 141
TABLE 94 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 142
TABLE 95 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 142
TABLE 96 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 142
6.4.8 BIOANALYTICAL TESTING SERVICES 143
6.4.8.1 High demand for bioanalytical testing due to growing use of macromolecules and biosimilars 143
TABLE 97 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 143
TABLE 98 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 143
TABLE 99 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 144
TABLE 100 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 144
6.5 CONSULTING SERVICES 144
6.5.1 INCREASING ADOPTION OF CONSULTING SERVICES FOR QUALITY ASSURANCE PURPOSES PROPELS SEGMENT GROWTH 144
TABLE 101 CONSULTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 145
TABLE 102 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 145
TABLE 103 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 146
TABLE 104 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 146
6.6 DATA MANAGEMENT SERVICES 146
6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD 146
TABLE 105 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 147
TABLE 106 DATA MANAGEMENT SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 148
TABLE 107 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 148
TABLE 108 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 149
TABLE 109 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 149
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA 150
7.1 INTRODUCTION 151
TABLE 110 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 151
7.2 ONCOLOGY 152
7.2.1 INCREASING NUMBER OF CANCER CASES DRIVES GROWTH OF SEGMENT 152
FIGURE 35 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020) 152
FIGURE 36 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS) 153
TABLE 111 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020) 153
TABLE 112 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION,
2019–2026 (USD MILLION) 154
TABLE 113 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 154
TABLE 114 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 155
TABLE 115 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 155
 
7.3 INFECTIOUS DISEASES 155
7.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES 155
TABLE 116 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION,
2019–2026 (USD MILLION) 156
TABLE 117 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 156
TABLE 118 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 157
TABLE 119 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 157
7.4 NEUROLOGY 157
7.4.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS DRIVES MARKET 157
TABLE 120 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) 158
TABLE 121 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,
2019–2026 (USD MILLION) 159
TABLE 122 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 159
TABLE 123 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 159
TABLE 124 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 160
7.5 CARDIOVASCULAR SYSTEM DISORDERS 160
7.5.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 160
TABLE 125 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) 161
TABLE 126 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,
BY REGION, 2019–2026 (USD MILLION) 161
TABLE 127 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 162
TABLE 128 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 162
TABLE 129 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 162
7.6 METABOLIC DISORDERS/ENDOCRINOLOGY 163
7.6.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE MARKET GROWTH 163
FIGURE 37 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM
2000 TO 2045 (IN MILLIONS) 163
TABLE 130 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY,
BY REGION, 2019–2026 (USD MILLION) 164
TABLE 131 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 164
TABLE 132 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 164
TABLE 133 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 165
7.7 IMMUNOLOGICAL DISORDERS 165
7.7.1 GROWING IMMUNOLOGIAL DRUGS PIPELINE RESULTING IN INCREASE IN OUTSOURCING ACTIVITIES 165
TABLE 134 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2019–2026 (USD MILLION) 166
TABLE 135 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 166
TABLE 136 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 166
TABLE 137 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 167
7.8 RESPIRATORY DISORDERS 167
7.8.1 INCREASING PREVALENCE OF RESPIRATORY DISEASE TO SUPPORT GROWTH OF SEGMENT 167
TABLE 138 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020) 168
TABLE 139 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2019–2026 (USD MILLION) 169
TABLE 140 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 169
TABLE 141 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 169
TABLE 142 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 170
7.9 PSYCHIATRY 170
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH 170
TABLE 143 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2019–2026 (USD MILLION) 171
TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019–2026 (USD MILLION) 171
TABLE 145 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2019–2026 (USD MILLION) 171
TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019–2026 (USD MILLION) 172
7.10 DERMATOLOGY 172
7.10.1 INCREASING PREVALENCE OF SKIN DISORDERS PROPELS SEGMENT GROWTH 172
TABLE 147 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020) 173
TABLE 148 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION,
2019–2026 (USD MILLION) 173
TABLE 149 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2019–2026 (USD MILLION) 174
TABLE 150 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 174
TABLE 151 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 174
 
7.11 HEMATOLOGY 175
7.11.1 DEVELOPMENT OF DRUGS FOR HEMATOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 175
TABLE 152 CRO SERVICES MARKET FOR HAEMATOLOGY, BY REGION,
2019–2026 (USD MILLION) 175
TABLE 153 NORTH AMERICA: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 175
TABLE 154 EUROPE: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 176
TABLE 155 ASIA PACIFIC: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 176
7.12 OPHTHALMOLOGY 176
7.12.1 GROWING NEED FOR OPTHALMOLOGY-RELATED CLINICAL TRIALS 176
TABLE 156 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,
2019–2026 (USD MILLION) 177
TABLE 157 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2019–2026 (USD MILLION) 177
TABLE 158 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 177
TABLE 159 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 178
7.13 GASTROINTESTINAL DISEASES 178
7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES AND GROWING INVESTMENT IN R&D TO PROPEL MARKET 178
TABLE 160 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2019–2026 (USD MILLION) 179
TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 179
TABLE 162 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 179
TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 180
7.14 GENITOURINARY & WOMEN’S HEALTH 180
7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN DRIVES SEGMENT GROWTH 180
TABLE 164 CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,
BY REGION, 2019–2026 (USD MILLION) 181
TABLE 165 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD MILLION) 181
TABLE 166 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD MILLION) 181
TABLE 167 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD MILLION) 182
7.15 OTHER THERAPEUTIC AREAS 182
7.15.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPPORT SEGMENT GROWTH 182
TABLE 168 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019–2026 (USD MILLION) 183
TABLE 169 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 183
TABLE 170 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2019–2026 (USD MILLION) 183
TABLE 171 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2019–2026 (USD MILLION) 184
8 CRO SERVICES MARKET, BY MOLECULE TYPE 185
8.1 INTRODUCTION 186
TABLE 172 CRO SERVICES MARKET, BY MOLECULE TYPE, 2019–2026 (USD MILLION) 186
8.2 VACCINES 186
8.2.1 RISING FOCUS ON IMMUNIZATION FOR INFECTIOUS DISEASES FUELING MARKET GROWTH 186
TABLE 173 COVID-19 VACICNES IN PIPELINE 187
TABLE 174 CRO SERVICES MARKET FOR VACCINES, BY REGION,
2019–2026 (USD MILLION) 187
8.3 CELL & GENE THERAPY 187
8.3.1 INCREASING FUNDING FOR R&D SUPPORTS MARKET GROWTH 187
8.4 OTHER MOLECULE TYPES 188
9 CRO SERVICES MARKET, BY END USER 190
9.1 INTRODUCTION 191
TABLE 175 CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 191
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 191
9.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINE TO DRIVE MARKET GROWTH 191
FIGURE 38 ANNUAL DRUG APPROVALS BY FDA’S CDER (2009–2018) 192
FIGURE 39 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011–2018 193
TABLE 176 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2019–2026 (USD MILLION) 194
TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2019–2026 (USD MILLION) 194
TABLE 178 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2019–2026 (USD MILLION) 194
TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2019–2026 (USD MILLION) 195
9.3 MEDICAL DEVICE COMPANIES 195
9.3.1 INCREASE IN R&D FOR DEVELOPMENT OF ADVANCED MEDICAL DEVICES FUELING MARKET GROWTH 195
FIGURE 40 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2010–2020) 196
FIGURE 41 R&D EXPENSES OF LEADING MEDICAL DEVICE COMPANIES
(IN USD MILLION), 2020 197
TABLE 180 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2019–2026 (USD MILLION) 197
TABLE 181 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 198
TABLE 182 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2019–2026 (USD MILLION) 198
TABLE 183 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 198
9.4 ACADEMIC INSTITUTES 199
9.4.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT 199
TABLE 184 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION,
2019–2026 (USD MILLION) 200
TABLE 185 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2019–2026 (USD MILLION) 200
TABLE 186 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 200
TABLE 187 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2019–2026 (USD MILLION) 201
10 CRO SERVICES MARKET, BY REGION 202
10.1 INTRODUCTION 203
TABLE 188 CRO SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 203
10.2 NORTH AMERICA 203
FIGURE 42 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT 204
TABLE 189 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 205
TABLE 190 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 205
TABLE 191 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION) 205
TABLE 192 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 206
TABLE 193 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 206
TABLE 194 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 206
TABLE 195 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 207
TABLE 196 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 207
TABLE 197 NORTH AMERICA: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 208
10.2.1 US 208
10.2.1.1 Largest CRO services market in North America due to robust clinical trial activities 208
FIGURE 43 US CONTINUES TO DOMINATE DISTRIBUTION OF R&D COMPANIES
BY REGION (2020 VS. 2019) 209
TABLE 198 US: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 209
TABLE 199 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 210
TABLE 200 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 210
TABLE 201 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 210
TABLE 202 US: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 211
TABLE 203 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 211
TABLE 204 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 211
TABLE 205 US: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 212
10.2.2 CANADA 212
10.2.2.1 Increasing number of clinical trials to support market growth 212
TABLE 206 CANADA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 213
TABLE 207 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 213
TABLE 208 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 213
TABLE 209 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 214
TABLE 210 CANADA: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 214
TABLE 211 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 214
TABLE 212 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 215
TABLE 213 CANADA: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 215

Pharmaceutical Packaging Equipment Market by Product (Aseptic Packaging, Blister, Strip, Bottle, Tube, Carton, Case Packer, Wrapping Machine, Palletiz...

Publisher:        MarketsandMarkets

# of Pages:        378

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS AND EXCLUSIONS 40
1.3 MARKET SCOPE 41
1.3.1 MARKETS COVERED 41
FIGURE 1 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SEGMENTATION 41
1.3.2 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: BY REGION 42
1.4 YEARS CONSIDERED FOR THE STUDY 42
1.5 CURRENCY 43
TABLE 1 STANDARD CURRENCY CONVERSION RATES 43
1.6 LIMITATIONS 43
1.7 STAKEHOLDERS 43
1.8 SUMMARY OF CHANGES 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 2 RESEARCH DESIGN 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Key data from secondary sources 47
2.1.2 PRIMARY DATA 48
FIGURE 3 PRIMARY SOURCES 48
2.1.2.1 Key data from primary sources 49
2.1.2.2 Key industry insights 50
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 50
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 51
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 51
2.2 MARKET SIZE ESTIMATION 52
FIGURE 7 SUPPLY SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 52
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: SYNTEGON TECHNOLOGY GMBH 53
FIGURE 9 SUPPLY SIDE MARKET SIZE ESTIMATION: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET (2020) 54
FIGURE 10 APPROACH 3: BASED ON SOURCE, BY REGION (2022) 55
FIGURE 11 TOP-DOWN APPROACH 55
FIGURE 12 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES ANALYSIS (2022–2027) 57
FIGURE 13 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 57
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 58
FIGURE 14 DATA TRIANGULATION METHODOLOGY 59
2.4 MARKET SHARE ESTIMATION 60
2.5 ASSUMPTIONS FOR THE STUDY 60
2.6 LIMITATIONS 60
2.6.1 METHODOLOGY-RELATED LIMITATIONS 61
2.7 RISK ASSESSMENT 61
TABLE 2 RISK ASSESSMENT: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 61
2.8 ASSESSMENT OF COVID-19 IMPACT ON ECONOMIC SCENARIO 61
3 EXECUTIVE SUMMARY 63
FIGURE 15 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION) 63
FIGURE 16 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 64
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 65
4 PREMIUM INSIGHTS 66
4.1 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET OVERVIEW 66
FIGURE 18 RISING NEED FOR FLEXIBLE AND INTEGRATED PACKAGING EQUIPMENT TO DRIVE MARKET GROWTH 66
4.2 ASIA PACIFIC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT AND COUNTRY (2021) 67
FIGURE 19 PRIMARY PACKAGING EQUIPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF APAC MARKET IN 2021 67
4.3 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
FIGURE 20 CHINA TO REGISTER THE HIGHEST GROWTH DURING FORECAST PERIOD 68
4.4 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, REGIONAL MIX, 2022−2027 68
FIGURE 21 EUROPE TO DOMINATE PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 68
4.5 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DEVELOPING VS. DEVELOPED MARKETS 69
FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING
FORECAST PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 23 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 High growth in generics & biopharmaceuticals markets 71
FIGURE 24 SALES OF GENERIC DRUGS GLOBALLY, 2006–2020 (USD BILLION) 71
FIGURE 25 GLOBAL PHARMACEUTICALS MARKET (USD BILLION) 71
TABLE 3 LIST OF OFF-PATENT DRUGS, 2015−2029 72
5.2.1.2 Growing need for flexible and integrated packaging equipment 73
5.2.1.3 Increase in offshore pharmaceutical manufacturing 73
FIGURE 26 PHARMACEUTICAL IMPORTS AND EXPORTS, BY COUNTRY,
2020 (USD BILLION) 74
5.2.1.4 Growing contract manufacturing of pharmaceutical products 74
5.2.1.5 Introduction of regulatory standards on packaging and stringent norms against counterfeit products 74
TABLE 4 KEY REGULATIONS & STANDARDS GOVERNING PHARMACEUTICAL PACKAGING EQUIPMENT 75
5.2.1.6 Innovation in pharmaceutical packaging and delivery system 75
5.2.1.7 Growth in OTC drug sales and regulations to reduce OTC counterfeit 76
FIGURE 27 GLOBAL OTC PHARMACEUTICALS MARKET SIZE, 2020 (USD BILLION) 76
5.2.2 RESTRAINTS 76
5.2.2.1 Growing preference for refurbished equipment 76
5.2.3 OPPORTUNITIES 77
5.2.3.1 Growth of pharmaceutical manufacturing in emerging economies 77
5.2.3.2 Rising demand for automated packaging 77
5.2.3.3 Change in medication systems to self-medication and self-care 78
5.2.3.4 Increasing pharmaceutical R&D investments 78
FIGURE 28 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE,
2017–2024 79
FIGURE 29 NUMBER OF REGISTERED STUDIES, 2001-2022
(AS OF FEBRUARY 22, 2022) 79
FIGURE 30 NUMBER OF PIPELINE DRUGS, BY COMPANY, 2019 80
5.2.4 CHALLENGES 80
5.2.4.1 Growth in personalized and precision medicine supply chain 80
5.2.4.2 Uncertainties in regulations and standards of pharmaceutical packaging process 81
5.3 TECHNOLOGICAL ROADMAP 82
FIGURE 31 PHARMACEUTICAL PACKAGING EQUIPMENT: TECHNOLOGICAL ROADMAP 82
5.4 INDUSTRY TRENDS 83
FIGURE 32 MAJOR TRENDS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 83
5.4.1 DEVELOPMENT OF PRODUCTION LINES FOR SMALL BATCH SIZES AND RESEARCH PURPOSES 83
5.4.2 AUTOMATION AND INTEGRATION OF PACKAGING EQUIPMENT 84
5.4.3 GROWING FOCUS ON LABELING AND SERIALIZATION FOR ANTI-COUNTERFEITING OF DRUGS 85
5.4.4 GROWING DEMAND FOR ASEPTIC FILLING AND SEALING EQUIPMENT 85
5.5 PRICING ANALYSIS 86
TABLE 5 AVERAGE SELLING PRICE (USD): PRIMARY PACKAGING EQUIPMENT 86
TABLE 6 AVERAGE SELLING PRICE (USD): SECONDARY PACKAGING EQUIPMENT 87
TABLE 7 AVERAGE SELLING PRICE (USD): LABELING AND SERIALIZATION EQUIPMENT 87
5.6 SUPPLY CHAIN ANALYSIS 87
FIGURE 33 SUPPLY CHAIN ANALYSIS 88
5.7 VALUE CHAIN ANALYSIS 88
FIGURE 34 VALUE CHAIN OF PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 89
5.8 ECOSYSTEM MARKET MAP 89
FIGURE 35 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET:
ECOSYSTEM MARKET MAP 89
5.9 PORTER’S FIVE FORCES ANALYSIS 90
TABLE 8 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 90
5.10 REGULATORY ANALYSIS 92
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 92
TABLE 11 ASIA-PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 12 REST OF WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
5.10.2 NORTH AMERICA 94
5.10.2.1 US 94
5.10.2.2 CANADA 94
5.10.3 EUROPE 95
5.10.4 ASIA PACIFIC 95
5.10.4.1 Japan 95
5.10.4.2 China 95
5.10.4.3 India 95
5.10.5 BRAZIL 96
FIGURE 36 BRAZIL: REGULATORY PROCESS FOR PHARMACEUTICAL PACKAGING EQUIPMENT 96
5.11 KEY CONFERENCES & EVENTS IN 2022-2023 97
TABLE 13 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DETAILED LIST OF CONFERENCES & EVENTS 97
5.12 YC–YCC TRENDS/DISRUPTION IMPACTING CUSTOMER BUSINESS 98
FIGURE 37 YC–YCC SHIFT IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 98
5.13 PATENT ANALYSIS 98
5.13.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL PACKAGING EQUIPMENT 98
FIGURE 38 GLOBAL PATENT PUBLICATION TRENDS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, 2015–2021 99
5.13.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 99
FIGURE 39 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PHARMACEUTICAL PACKAGING EQUIPMENT PATENTS,
2015–2021 99
5.14 TRADE ANALYSIS 100
TABLE 14 PHARMACEUTICAL PACKAGING EQUIPMENT EXPORT AND IMPORT DATA,
BY COUNTRY 100
5.15 CASE STUDY ANALYSIS 101
FIGURE 40 CASE STUDY: SECURITY PACKAGING UPGRADES FOR PHARMACEUTICAL 101
5.15.1 CASE STUDY: QUALITATIVE INSIGHT BASED ON SPEED OF THE MACHINE 102
5.15.1.1 Sachet packaging equipment: 102
5.15.1.2 Blister packaging equipment: 102
5.15.1.3 Cartoning equipment: 104
5.16 IMPACT OF COVID-19 ON PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 107
6 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT 109
6.1 INTRODUCTION 110
TABLE 15 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 110
6.2 PRIMARY PACKAGING EQUIPMENT 110
TABLE 16 PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 111
TABLE 17 PRIMARY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 112
6.2.1 ASEPTIC FILLING AND SEALING EQUIPMENT 112
6.2.1.1 Technological advancements and automation to drive segment growth 112
TABLE 18 EXAMPLES OF ASEPTIC FILLING AND SEALING EQUIPMENT 113
TABLE 19 ASEPTIC FILLING AND SEALING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 116
6.2.2 BOTTLE FILLING AND CAPPING EQUIPMENT 116
6.2.2.1 Higher adoption of plastic bottles in pharmaceutical packaging to support segment growth 116
TABLE 20 EXAMPLES OF BOTTLE FILLING AND CAPPING EQUIPMENT 117
TABLE 21 BOTTLE FILLING AND CAPPING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 118
6.2.3 BLISTER PACKAGING EQUIPMENT 118
6.2.3.1 Adaptability of blister packs to impact blister packaging equipment demand 118
TABLE 22 EXAMPLES OF BLISTER PACKAGING EQUIPMENT 119
TABLE 23 BLISTER PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 121
6.2.4 SOFT-TUBE FILLING AND SEALING EQUIPMENT 122
6.2.4.1 Increasing demand for soft-tube-based drug formulations and OTC pain relief ointments and creams to aid market growth 122
TABLE 24 EXAMPLES OF SOFT-TUBE FILLING AND SEALING EQUIPMENT 122
TABLE 25 SOFT-TUBE FILLING AND SEALING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
6.2.5 SACHET PACKAGING EQUIPMENT 124
6.2.5.1 Increasing applications of sachets and pouches in unit dose packaging to drive segment growth 124
TABLE 26 EXAMPLES OF SACHET PACKAGING EQUIPMENT 124
TABLE 27 SACHET PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 125
6.2.6 STRIP PACKAGING EQUIPMENT 125
6.2.6.1 User-friendly packaging of strips to drive segment growth 125
TABLE 28 EXAMPLES OF STRIP PACKAGING EQUIPMENT 126
TABLE 29 STRIP PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 127
6.2.7 COUNTING EQUIPMENT 127
6.2.7.1 Initiatives to develop remote tablet counting machines to improve accuracy and efficiency in medical dispensing 127
TABLE 30 EXAMPLES OF COUNTING EQUIPMENT 128
TABLE 31 COUNTING EQUIPMENT MARKET, BY COUNTRY, 2020–2027(USD MILLION) 129
6.2.8 OTHER PRIMARY PACKAGING EQUIPMENT 129
TABLE 32 OTHER PRIMARY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027(USD MILLION) 130
6.3 SECONDARY PACKAGING EQUIPMENT 130
TABLE 33 SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 131
TABLE 34 SECONDARY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 132
6.3.1 CARTONING EQUIPMENT 132
6.3.1.1 Safe and gentle packaging achieved with cartoning equipment usage to drive segment growth 132
TABLE 35 EXAMPLES OF CARTONING EQUIPMENT 133
TABLE 36 CARTONING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
6.3.2 CASE PACKING EQUIPMENT 135
6.3.2.1 Increasing demand for flexible packaging to support market growth 135
TABLE 37 EXAMPLES OF CASE PACKING EQUIPMENT 136
TABLE 38 CASE PACKING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 137
6.3.3 WRAPPING EQUIPMENT 137
6.3.3.1 Wrapping machines offer customization to increase productivity 137
TABLE 39 EXAMPLES OF WRAPPING EQUIPMENT 138
TABLE 40 WRAPPING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
6.3.4 TRAY PACKING EQUIPMENT 139
6.3.4.1 Technological advances to support segment growth 139
TABLE 41 EXAMPLES OF TRAY PACKING EQUIPMENT 140
TABLE 42 TRAY PACKING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
6.3.5 PALLETIZING AND DEPALLETIZING EQUIPMENT 141
6.3.5.1 Recent developments and automation in palletizing and depalletizing equipment to drive market growth 141
TABLE 43 EXAMPLES OF PALLETIZING AND DEPALLETIZING EQUIPMENT 141
TABLE 44 PALLETIZING AND DEPALLETIZING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142
6.4 LABELING AND SERIALIZATION EQUIPMENT 142
TABLE 45 LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 143
TABLE 46 LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 144
6.4.1 BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT 144
6.4.1.1 Increasing awareness about anti-counterfeit technologies to drive market growth 144
TABLE 47 EXAMPLES OF BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT 145
TABLE 48 BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 146
6.4.2 CARTON LABELING AND SERIALIZATION EQUIPMENT 146
6.4.2.1 Increasing demand for pharmaceutical products labeling and serialization to drive market growth 146
TABLE 49 EXAMPLES OF CARTON LABELING AND SERIALIZATION EQUIPMENT 147
TABLE 50 CARTON LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
6.4.3 DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT 148
6.4.3.1 Speed and ease of use to propel segment growth 148
TABLE 51 EXAMPLES OF DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT 148
TABLE 52 DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 149
7 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE 150
7.1 INTRODUCTION 151
TABLE 53 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 151
7.2 LIQUID PACKAGING EQUIPMENT 151
TABLE 54 LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 152
TABLE 55 LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 152
7.2.1 ASEPTIC LIQUIDS 153
7.2.1.1 Automation of packaging lines and increasing use of robotics to propel aseptic liquid packaging 153
TABLE 56 EXAMPLES OF ASEPTIC LIQUID PACKAGING EQUIPMENT 154
TABLE 57 ASEPTIC LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 157
7.2.2 SYRUPS 158
7.2.2.1 Bottle filling and capping machines to reduce syrup spillage risk 158
TABLE 58 EXAMPLES OF SYRUP PACKAGING EQUIPMENT 158
TABLE 59 SYRUP PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 159
7.2.3 EYE/EAR DROPS 159
7.2.3.1 Technological advancements to increase demand for automated form-fill-seal equipment used for eye/ear drops packaging 159
TABLE 60 EXAMPLES OF EYE/EAR DROP PACKAGING EQUIPMENT 160
TABLE 61 EYE/EAR DROP PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 160
7.2.4 AEROSOLS 161
7.2.4.1 Integration of filling and sealing processes to gain importance in aerosol packaging 161
TABLE 62 EXAMPLES OF AEROSOL PACKAGING EQUIPMENT 161
TABLE 63 AEROSOL PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
7.2.5 OTHER LIQUID PACKAGING EQUIPMENT 162
TABLE 64 OTHER LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 163
7.3 SOLID PACKAGING EQUIPMENT 163
TABLE 65 SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 66 SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 164
7.3.1 TABLETS 165
7.3.1.1 Growing demand for packaging equipment capable of handling smaller batch sizes with higher levels of accuracy and precision to drive segment growth 165
TABLE 67 EXAMPLES OF TABLET PACKAGING EQUIPMENT 165
TABLE 68 TABLET PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 168
7.3.2 CAPSULES 168
7.3.2.1 Capsule-counting machines to integrate with filling and inspection systems 168
TABLE 69 EXAMPLES OF CAPSULE PACKAGING EQUIPMENT 169
TABLE 70 CAPSULE PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 170
7.3.3 POWDERS 170
7.3.3.1 High demand for robotic packaging equipment for powder packaging to proper segment growth 170
TABLE 71 EXAMPLES OF POWDER PACKAGING EQUIPMENT 171
TABLE 72 POWDER PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 172
7.3.4 GRANULES 172
7.3.4.1 Sachets to become most preferred packaging forms for granules 172
TABLE 73 EXAMPLES OF GRANULE PACKAGING EQUIPMENT 173
TABLE 74 GRANULE PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 173
7.3.5 OTHER SOLID PACKAGING EQUIPMENT 174
TABLE 75 OTHER SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 174
7.4 SEMI-SOLID PACKAGING EQUIPMENT 175
TABLE 76 SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 175
TABLE 77 SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 176
7.4.1 OINTMENTS 176
7.4.1.1 Wide usage to drive pharmaceutical packaging equipment demand 176
TABLE 78 EXAMPLES OF OINTMENT PACKAGING EQUIPMENT 177
TABLE 79 OINTMENT PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 178
7.4.2 CREAMS 178
7.4.2.1 Filling, capping, and sealing machines to package creams 178
TABLE 80 CREAM PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 179
7.4.3 SUPPOSITORIES 179
7.4.3.1 Drying drug pipelines and growing costs to limit segment growth 179
TABLE 81 SUPPOSITORY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 180
7.4.4 OTHER SEMI-SOLID PACKAGING EQUIPMENT 180
TABLE 82 OTHER SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 181
7.5 OTHER PRODUCT PACKAGING EQUIPMENT 181
TABLE 83 OTHER PRODUCT PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 182
8 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY REGION 183
8.1 INTRODUCTION 184
FIGURE 41 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 184
TABLE 84 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY REGION,
2020–2027 (USD MILLION) 185
8.2 EUROPE 185
FIGURE 42 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SNAPSHOT 186
TABLE 85 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 187
TABLE 86 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 187
TABLE 87 EUROPE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 188
TABLE 88 EUROPE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 188
TABLE 89 EUROPE: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 90 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 91 EUROPE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 190
TABLE 92 EUROPE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 190
TABLE 93 EUROPE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 191
8.2.1 GERMANY 191
8.2.1.1 Germany to witness highest growth rate in European market 191
TABLE 94 GERMANY: KEY MACROINDICATORS 192
TABLE 95 GERMANY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 192
TABLE 96 GERMANY: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 97 GERMANY: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 98 GERMANY: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 99 GERMANY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 100 GERMANY: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 195
TABLE 101 GERMANY: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 195
TABLE 102 GERMANY: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 196
8.2.2 ITALY 196
8.2.2.1 Growing consumption of OTC and generic drugs to drive market growth 196
TABLE 103 ITALY: KEY MACROINDICATORS 197
TABLE 104 ITALY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 197
TABLE 105 ITALY: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 198
TABLE 106 ITALY: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 198
TABLE 107 ITALY: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 199
TABLE 108 ITALY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 199
TABLE 109 ITALY: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 200
TABLE 110 ITALY: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 200
TABLE 111 ITALY: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 201
8.2.3 UK 201
8.2.3.1 Growth in generics market alongside rising demand for prescription and OTC drugs to drive market growth 201
TABLE 112 UK: KEY MACROINDICATORS 201
TABLE 113 UK: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 202
TABLE 114 UK: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 202
TABLE 115 UK: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 203
TABLE 116 UK: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 203
TABLE 117 UK: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 204
TABLE 118 UK: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 204
TABLE 119 UK: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 205
TABLE 120 UK: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 205
8.2.4 FRANCE 206
8.2.4.1 Presence of leading pharmaceutical companies to drive market growth 206
TABLE 121 FRANCE: KEY MACROINDICATORS 206
TABLE 122 FRANCE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 206
TABLE 123 FRANCE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 207
TABLE 124 FRANCE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 207
TABLE 125 FRANCE: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 126 FRANCE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 127 FRANCE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 209
TABLE 128 FRANCE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 209
TABLE 129 FRANCE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 210
8.2.5 SPAIN 210
8.2.5.1 Rising geriatric population and growing generics market to propel market growth 210
TABLE 130 SPAIN: KEY MACROINDICATORS 211
TABLE 131 SPAIN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 211
TABLE 132 SPAIN: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 212
TABLE 133 SPAIN: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 212
TABLE 134 SPAIN: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 213
TABLE 135 SPAIN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 136 SPAIN: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 214
TABLE 137 SPAIN: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 214
TABLE 138 SPAIN: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 215
8.2.6 SWITZERLAND 215
8.2.6.1 Growing generics market to drive market growth 215
TABLE 139 SWITZERLAND: KEY MACROINDICATORS 216
TABLE 140 SWITZERLAND: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 216
TABLE 141 SWITZERLAND: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 217
TABLE 142 SWITZERLAND: SECONDARY PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 143 SWITZERLAND: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 144 SWITZERLAND: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 145 SWITZERLAND: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 219
TABLE 146 SWITZERLAND: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 219
TABLE 147 SWITZERLAND: SEMI-SOLID PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 220
8.2.7 REST OF EUROPE 220
TABLE 148 ROE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221
TABLE 149 ROE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 221
TABLE 150 ROE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 222
TABLE 151 ROE: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 222
TABLE 152 ROE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 223
TABLE 153 ROE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 223
TABLE 154 ROE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 224
TABLE 155 ROE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 224
8.3 ASIA PACIFIC 225
FIGURE 43 ASIA PACIFIC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SNAPSHOT 226
TABLE 156 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 227
TABLE 157 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 227
TABLE 158 APAC: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 228
TABLE 159 APAC: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 228
TABLE 160 APAC: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 229
TABLE 161 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 229
TABLE 162 APAC: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 230
TABLE 163 APAC: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 230
TABLE 164 APAC: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 231
8.3.1 CHINA 231
8.3.1.1 Favorable government initiatives to propel market growth 231
TABLE 165 CHINA: KEY MACROINDICATORS 232
TABLE 166 CHINA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 232
TABLE 167 CHINA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 233
TABLE 168 CHINA: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 233
TABLE 169 CHINA: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 234
TABLE 170 CHINA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 171 CHINA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 235
TABLE 172 CHINA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 235
TABLE 173 CHINA: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 236
8.3.2 JAPAN 236
8.3.2.1 Rising geriatric population and growth in generics market to drive market growth 236
TABLE 174 JAPAN: KEY MACROINDICATORS 237
TABLE 175 JAPAN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 237
TABLE 176 JAPAN: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 238
TABLE 177 JAPAN: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 238
TABLE 178 JAPAN: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 239
TABLE 179 JAPAN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 180 JAPAN: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 240
TABLE 181 JAPAN: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 240
TABLE 182 JAPAN: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 241
8.3.3 INDIA 241
8.3.3.1 Low manufacturing cost and skilled workforce to attract outsourcing and investments 241
TABLE 183 INDIA: KEY MACROINDICATORS 242
TABLE 184 INDIA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 242
TABLE 185 INDIA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 243
TABLE 186 INDIA: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 243
TABLE 187 INDIA: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 244
TABLE 188 INDIA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 244
TABLE 189 INDIA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 245
TABLE 190 INDIA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 245
TABLE 191 INDIA: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 246
8.3.4 SOUTH KOREA 246
8.3.4.1 Rising healthcare spending and increasing government initiatives to propel clinical trials 246
TABLE 192 COUNTRIES BUYING THE MOST KOREAN DRUGS 247
TABLE 193 SOUTH KOREA: KEY MACROINDICATORS 247
TABLE 194 SOUTH KOREA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 247
TABLE 195 SOUTH KOREA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 248
TABLE 196 SOUTH KOREA: SECONDARY PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 248
TABLE 197 SOUTH KOREA: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 198 SOUTH KOREA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 199 SOUTH KOREA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 250
TABLE 200 SOUTH KOREA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 250
TABLE 201 SOUTH KOREA: SEMI-SOLID PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 251
8.3.5 REST OF APAC 251
TABLE 202 ROAPAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 252
TABLE 203 ROAPAC: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 252
TABLE 204 ROAPAC: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 253
TABLE 205 ROAPAC: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 206 ROAPAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 207 ROAPAC: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 254
TABLE 208 ROAPAC: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 255
TABLE 209 ROAPAC: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 255

Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Lab, Consulting), Therapeutic Area (Oncology, Infectious Disease...

Publisher:        MarketsandMarkets

# of Pages:        408

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 55
1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 56
1.2.1 INCLUSIONS & EXCLUSIONS 56
1.3 MARKET SCOPE 57
FIGURE 1 CRO SERVICES MARKET 57
1.3.1 YEARS CONSIDERED FOR THE STUDY 58
1.4 CURRENCY 58
1.5 LIMITATIONS 58
1.6 STAKEHOLDERS 59
1.7 SUMMARY OF CHANGES 59
2 RESEARCH METHODOLOGY 61
2.1 RESEARCH DATA 61
FIGURE 2 RESEARCH DESIGN 61
2.1.1 SECONDARY DATA 62
2.1.2 PRIMARY DATA 62
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES 63
2.2 MARKET SIZE ESTIMATION 64
FIGURE 4 MARKET SIZE ESTIMATION—BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET 64
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021 64
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021 65
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 66
FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2022–2027 67
FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES 67
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 68
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 69
FIGURE 10 DATA TRIANGULATION METHODOLOGY 69
2.5 INSIGHTS FROM PRIMARIES 70
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 70
2.6 RESEARCH ASSUMPTIONS 70
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 71
2.7 RISK ANALYSIS 71
3 EXECUTIVE SUMMARY 72
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 72
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2022 VS. 2027 (USD MILLION) 73
FIGURE 14 CRO SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 74
FIGURE 15 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET 75
4 PREMIUM INSIGHTS 76
4.1 CRO SERVICES MARKET OVERVIEW 76
FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 76
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY SERVICE & COUNTRY (2021) 77
FIGURE 17 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN CRO SERVICES MARKET IN 2021 77
4.3 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 78
FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2027 78
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2021 78
FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021 78
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 79
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CRO SERVICES MARKET FROM 2022 TO 2027 79
5 MARKET OVERVIEW 80
5.1 INTRODUCTION 80
5.2 MARKET DYNAMICS 80
FIGURE 21 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 80
TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS 81
5.2.1 DRIVERS 81
5.2.1.1 Increasing investment in pharmaceutical R&D 81
FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 82
FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021 83
5.2.1.2 Increasing number of clinical trial 83
FIGURE 24 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021) 83
5.2.1.3 High cost of in-house drug development 84
FIGURE 25 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 84
5.2.1.4 Rising prevalence of orphan and rare diseases 85
5.2.2 OPPORTUNITIES 85
5.2.2.1 Growth in the drugs and biologics market despite the COVID-19 pandemic 85
FIGURE 26 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY THE US FDA (2011–2021) 85
TABLE 2 LIST OF BIOLOGICS APPROVED BY THE US FDA (2021) 86
5.2.2.2 Rising demand for specialized testing services among end users 86
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 87
5.2.3 CHALLENGES 87
5.2.3.1 Shortage of skilled professionals for clinical trials 87
5.2.3.2 Requirement for unique analytical testing approaches for innovative formulations 88
5.2.4 MARKET TRENDS 88
5.2.4.1 Growing adoption of artificial intelligence-based tools for drug discovery 88
5.2.4.2 Increased outsourcing to emerging Asian economies 89
5.2.4.3 CRO industry consolidation 90
TABLE 3 LIST OF ACQUISITIONS 90
5.2.4.4 Integrated end-to-end R&D service solutions 91
5.3 RANGES/SCENARIOS 91
FIGURE 27 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CRO SERVICES MARKET 91
5.4 IMPACT OF COVID-19 OUTBREAK ON THE CRO SERVICES MARKET 92
FIGURE 28 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021 92
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 94
FIGURE 29 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS 94
5.6 PRICING ANALYSIS 94
TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020) 95
5.7 VALUE CHAIN ANALYSIS 95
FIGURE 30 VALUE CHAIN ANALYSIS OF THE CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE 96
5.8 ECOSYSTEM ANALYSIS 97
FIGURE 31 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET 97
TABLE 5 SUPPLY CHAIN ECOSYSTEM 98
5.9 TECHNOLOGY ANALYSIS 99
5.10 CASE STUDIES 100
5.10.1 COVANCE FSPX DATA ANALYSIS WAS USED TO DETERMINE THE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIALS 100
5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR 100
5.11 KEY CONFERENCES & EVENTS IN 2022–2023 100
TABLE 6 CRO SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 100
5.12 REGULATORY ANALYSIS 101
5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
5.13 PORTER’S FIVE FORCES ANALYSIS 107
TABLE 11 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 107
5.13.1 THREAT OF NEW ENTRANTS 107
5.13.2 THREAT OF SUBSTITUTES 107
5.13.3 BARGAINING POWER OF BUYERS 108
5.13.4 BARGAINING POWER OF SUPPLIERS 108
5.13.5 DEGREE OF COMPETITION 108
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 109
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 109
FIGURE 32 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS OF CRO SERVICES 109
5.14.2 BUYING CRITERIA FOR CRO SERVICES 109
FIGURE 33 KEY BUYING CRITERIA FOR END USERS 109
6 CRO SERVICES MARKET, BY TYPE 110
6.1 INTRODUCTION 111
TABLE 12 CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
6.2 CLINICAL RESEARCH SERVICES 111
TABLE 13 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF MARCH 2022, BY LOCATION 112
TABLE 14 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS 112
FIGURE 34 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2020 VS. 2021 113
TABLE 15 CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 16 CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 114
TABLE 17 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 18 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 115
TABLE 19 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 20 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
6.2.1 PHASE III CLINICAL RESEARCH SERVICES 116
6.2.1.1 Rising cost of Phase III trials and high number of patients recruited in these trials to drive the demand for cost-effective CRO services 116
TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY 116
TABLE 22 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 117
TABLE 23 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 24 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 25 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 26 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 118
6.2.2 PHASE II CLINICAL RESEARCH SERVICES 118
6.2.2.1 Long duration of Phase II studies provides growth opportunities for CROs 118
TABLE 27 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES 119
TABLE 28 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 119
TABLE 29 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 30 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 31 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 32 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 121
6.2.3 PHASE I CLINICAL RESEARCH SERVICES 121
6.2.3.1 Robust pipeline of pharmaceutical companies driving the growth of this market segment 121
TABLE 33 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES 121
TABLE 34 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 122
TABLE 35 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 122
TABLE 36 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 37 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 38 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 123
6.2.4 PHASE IV CLINICAL RESEARCH SERVICES 124
6.2.4.1 Increasing number of CROs are providing post-marketing surveillance 124
TABLE 39 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES 124
TABLE 40 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 125
TABLE 41 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 42 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 43 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 44 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
6.3 EARLY-PHASE DEVELOPMENT SERVICES 126
FIGURE 35 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2021) 127
TABLE 45 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS 127
TABLE 46 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 128
TABLE 47 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 128
TABLE 48 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 49 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 50 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 51 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 130
6.3.1 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES 130
6.3.1.1 CMC services are widely used to check the quality standards of drugs 130
TABLE 52 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 130
TABLE 53 NORTH AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 54 EUROPE: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 55 ASIA PACIFIC: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 56 LATIN AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 132
6.3.2 PRECLINICAL SERVICES 132
TABLE 57 PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 58 PRECLINICAL SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 133
TABLE 59 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 133
TABLE 60 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 133
TABLE 61 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
TABLE 62 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
6.3.2.1 Pharmacokinetics/pharmacodynamics services 134
6.3.2.1.1 Importance of studies to determine the pharmacokinetic behavior of drug candidates is increasing 134
TABLE 63 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 135
TABLE 64 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 65 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 66 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 67 LATIN AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
6.3.2.2 Toxicology testing services 137
6.3.2.2.1 Demand for toxicology testing is increasing to prevent late-stage failures 137
TABLE 68 TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 137
TABLE 69 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 70 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 138
TABLE 71 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 72 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
6.3.2.3 Other preclinical services 139
TABLE 73 OTHER PRECLINICAL SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 139
TABLE 74 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 75 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
TABLE 76 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
TABLE 77 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
6.3.3 DISCOVERY STUDIES 141
6.3.3.1 Rising importance of CRO services for target identification and validation to promote segment growth 141
TABLE 78 DISCOVERY STUDIES MARKET, BY REGION, 2020–2027 (USD MILLION) 141
TABLE 79 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 80 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 81 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 82 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 143
6.4 LABORATORY SERVICES 143
TABLE 83 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 143
TABLE 84 LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
TABLE 85 LABORATORY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 144
TABLE 86 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 144
TABLE 87 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 145
TABLE 88 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 145
TABLE 89 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 145
6.4.1 ANALYTICAL TESTING SERVICES 146
TABLE 90 ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 146
TABLE 91 ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 146
TABLE 92 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 93 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 147
TABLE 94 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 95 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148
6.4.1.1 Physical characterization services 148
6.4.1.1.1 Demand for physical characterization is increasing to reduce the risk of product failure 148
TABLE 96 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 148
TABLE 97 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 98 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 99 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 100 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
6.4.1.2 Raw material testing services 150
6.4.1.2.1 Demand for raw material testing services is increasing to ensure the quality and purity of raw materials 150
TABLE 101 RAW MATERIAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 150
TABLE 102 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 151
TABLE 103 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 151
TABLE 104 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 151
TABLE 105 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152
6.4.1.3 Batch release testing services 152
6.4.1.3.1 Comprehensive portfolio of batch release testing services offered by CROs to propel segment growth 152
TABLE 106 BATCH RELEASE TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 152
TABLE 107 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 108 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 153
TABLE 109 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 110 LATIN AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 154
6.4.1.4 Stability testing services 154
6.4.1.4.1 Stability testing is used to ensure the long-term quality, safety, and efficacy of pharmaceutical products 154
TABLE 111 STABILITY TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 155
TABLE 112 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 155
TABLE 113 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 155
TABLE 114 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 156
TABLE 115 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156
6.4.1.5 Other analytical testing services 156
TABLE 116 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 157
TABLE 117 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
TABLE 118 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
TABLE 119 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
TABLE 120 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
6.4.2 BIOANALYTICAL TESTING SERVICES 158
6.4.2.1 Demand for bioanalytical testing has increased due to the growing use of macromolecules and biosimilars 158
TABLE 121 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 159
TABLE 122 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 123 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 159
TABLE 124 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
TABLE 125 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
6.5 CONSULTING SERVICES 160
6.5.1 ADOPTION OF CONSULTING SERVICES IS INCREASING FOR QUALITY ASSURANCE PURPOSES 160
TABLE 126 CONSULTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 161
TABLE 127 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 161
TABLE 128 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
TABLE 129 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
TABLE 130 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
6.6 DATA MANAGEMENT SERVICES 163
6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD 163
TABLE 131 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 163
TABLE 132 DATA MANAGEMENT SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 164
TABLE 133 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 134 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 164
TABLE 135 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 165
TABLE 136 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 165
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA 166
7.1 INTRODUCTION 167
TABLE 137 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 167
7.2 ONCOLOGY 168
FIGURE 36 GLOBAL CANCER INCIDENCE, BY CANCER TYPE (2020) 168
FIGURE 37 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM
2011 TO 2021 (IN THOUSAND) 169
TABLE 138 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2021) 169
TABLE 139 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2020–2027 (USD MILLION) 170
TABLE 140 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION,
2020–2027 (USD MILLION) 170
TABLE 141 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 142 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 171
TABLE 143 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 144 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 171
7.2.1 BREAST CANCER 172
7.2.1.1 Breast cancer is the most prevalent cancer 172
TABLE 145 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION,
2020–2027 (USD MILLION) 172
TABLE 146 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER,
BY COUNTRY, 2020–2027 (USD MILLION) 172
TABLE 147 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 148 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 149 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173
7.2.2 LUNG CANCER 174
7.2.2.1 Drug approvals indicate increasing research against lung cancer 174
TABLE 150 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION,
2020–2027 (USD MILLION) 174
TABLE 151 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 152 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY,
2020–2027 (USD MILLION) 175
TABLE 153 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 175
TABLE 154 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 175
7.2.3 COLORECTAL CANCER 176
7.2.3.1 Increasing number of clinical trials on treatments against colorectal cancer to drive segment growth 176
TABLE 155 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION,
2020–2027 (USD MILLION) 176
TABLE 156 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 176
TABLE 157 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 158 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 159 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177
7.2.4 PROSTATE CANCER 178
7.2.4.1 Increasing research initiatives on prostate cancer to drive segment growth 178
TABLE 160 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION,
2020–2027 (USD MILLION) 178
TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 178
TABLE 162 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179
TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179
TABLE 164 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179
7.2.5 OTHER CANCERS 180
TABLE 165 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION,
2020–2027 (USD MILLION) 180
TABLE 166 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 180
TABLE 167 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 168 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 169 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181
7.3 INFECTIOUS DISEASES 182
7.3.1 EPIDEMIC OUTBREAKS ARE NECESSITATING INCREASING DRUG DISCOVERY ACTIVITIES 182
TABLE 170 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION,
2020–2027 (USD MILLION) 182
TABLE 171 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 182
TABLE 172 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 173 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 174 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183
7.4 CARDIOVASCULAR SYSTEM DISORDERS 184
7.4.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 184
TABLE 175 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2021) 184
TABLE 176 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION) 185
TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 185
TABLE 178 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 185
TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 186
TABLE 180 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 186
7.5 NEUROLOGY 186
7.5.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 186
TABLE 181 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2021) 187
TABLE 182 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,
2020–2027 (USD MILLION) 188
TABLE 183 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 188
TABLE 184 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 188
TABLE 185 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 189
TABLE 186 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 189
7.6 VACCINES 189
7.6.1 INCREASING INVESTMENTS IN VACCINE R&D TO DRIVE SEGMENT GROWTH 189
TABLE 187 CRO SERVICES MARKET FOR VACCINES, BY REGION,
2020–2027 (USD MILLION) 190
TABLE 188 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 190
TABLE 189 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2020–2027 (USD MILLION) 190
TABLE 190 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2020–2027 (USD MILLION) 191
TABLE 191 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 191
7.7 METABOLIC DISORDERS/ENDOCRINOLOGY 191
7.7.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE SEGMENT GROWTH 191
FIGURE 38 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES,
2000–2045 (MILLION) 192
TABLE 192 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2020–2027 (USD MILLION) 192
TABLE 193 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 194 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 195 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 196 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 194
7.8 IMMUNOLOGICAL DISORDERS 194
7.8.1 GROWING DRUGS PIPELINE FOR IMMUNOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 194
TABLE 197 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 194
TABLE 198 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 199 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 200 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 201 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 196
7.9 PSYCHIATRY 196
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL SEGMENT GROWTH 196
TABLE 202 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION,
2020–2027 (USD MILLION) 196
TABLE 203 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 197
TABLE 204 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2020–2027 (USD MILLION) 197
TABLE 205 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 197
TABLE 206 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 198
7.10 RESPIRATORY DISORDERS 198
7.10.1 INCREASING PREVALENCE OF RESPIRATORY DISORDERS TO SUPPORT SEGMENT GROWTH 198
TABLE 207 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2021) 198
TABLE 208 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION,
2020–2027 (USD MILLION) 199
TABLE 209 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 199
TABLE 210 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200
TABLE 211 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200
TABLE 212 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200
7.11 DERMATOLOGY 201
7.11.1 INCREASING PREVALENCE OF SKIN DISORDERS TO PROPEL SEGMENT GROWTH 201
TABLE 213 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2021) 201
TABLE 214 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION,
2020–2027 (USD MILLION) 202
TABLE 215 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 202
TABLE 216 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 202
TABLE 217 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 203
TABLE 218 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 203
7.12 OPHTHALMOLOGY 203
7.12.1 GROWING NEED FOR OPHTHALMOLOGY-RELATED CLINICAL TRIALS TO DRIVE SEGMENT GROWTH 203
TABLE 219 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,
2020–2027 (USD MILLION) 204
TABLE 220 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 204
TABLE 221 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 204
TABLE 222 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 205
TABLE 223 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 205
7.13 GASTROINTESTINAL DISEASES 205
7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES TO PROPEL SEGMENT GROWTH 205
TABLE 224 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2020–2027 (USD MILLION) 206
TABLE 225 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 206
TABLE 226 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 206
TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 207
TABLE 228 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 207